Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenue:
Research and collaboration revenue	$ 1,294	$ 858
Operating Expenses:
Research and development	10,160	10,146
General and administrative	4,205	3,812
Total operating expenses	14,365	13,958
Loss from operations	(13,071)	(13,100)
Other (expense) income, net:
Interest income	910	588
Change in fair value of derivative tranche liability	(6,188)	0
Other income	18	79
Total other (expense) income, net	(5,260)	667
Net loss	$ (18,331)	$ (12,433)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.32)	$ (0.62)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.32)	$ (0.62)
Weighted-average shares of common stock outstanding, basic (in shares)	57,923,674	20,152,872
Weighted-average common shares outstanding, diluted (in shares)	57,923,674	20,152,872
Net loss attributable to common stockholders	$ (18,331)	$ (12,433)
Other comprehensive income (loss)	0	0
Total comprehensive loss	$ (18,331)	$ (12,433)